arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Outlook Therapeutics, Inc.

OTLK Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$0.52
▼ -7.3% Today
as of Oct 23, 15:35 ET
Last 30 days -18.81% Sep 14 → Oct 23
$0.45 $0.52 $0.58 $0.65 $0.71 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$0.56
High
$0.60
Low
$0.54
Volume
$4M
Avg Vol
$10M
Mkt Cap
$165M
P/E (TTM)
—
Beta
—
52w High
$2.54
52w Low
$0.16
Div Yield
—
Shares Out
$187M

Recent Press Releases & News last 60 days · 9 items

Oct 9 · 13:12 MT Newswires
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Oct 9 · 12:30 PR GlobeNewswire
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Oct 6 · 13:20 PR GlobeNewswire
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
▸ Show all 9 press releases & news Free account →

OTLK earnings at a glance

The options market is pricing a move of about ±50.2% after the report, a range of roughly $0.26 to $0.78 from today's $0.52. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±3.1% on average; after the most recent report on May 15, 2026 it moved -2.1%. That means options currently expect more movement than OTLK has typically delivered. OTLK beat the consensus EPS estimate in 1 of its last 3 reported quarters. Implied volatility is currently 362%. The share price of $0.52 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.16
$2.54
15% of range
Avg surprise (last 3)
-3.6%
Avg reaction (last 2)
-3.1%
0% positive
Latest IV / EM
362%
EM ±50.2% · $1 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-8.01$-5.83$-3.64$-1.46$0.72 Actual $-0.52Actual $-1.61Actual $-0.86Actual $-8.01Actual $-0.89Actual $0.72Actual $-0.40Est $-0.55Actual $-0.44Est $-0.42Actual $-0.38Actual $-0.16Est $-0.12Actual $-0.15 MarJunDecMarJunDecMar/2025Jun/2025DecMar/2026Jun
Revenue vs Net Income Revenue Net income
$-46M$-30M$-14M$2M$18M Dec 24Mar 25Jun 25Dec 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.15 — — — — financials
Fri May 15, 2026Mar/2026 $-0.16 $-0.12 -33.3% +60.0% -2.1% earnings
Wed Dec 31, 2025Dec 2025 $-0.38 — — — — financials
Thu Aug 14, 2025Jun/2025 $-0.44 $-0.42 -4.8% — — earnings
Thu May 15, 2025Mar/2025 $-0.40 $-0.55 +27.3% — -4.0% earnings
Tue Dec 31, 2024Dec 2024 $0.72 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.89 — — — — financials
Sun Mar 31, 2024Mar 2024 $-8.01 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.86 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.61 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.52 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————$2M———
Cost of revenue$16,965$149,327$29,626—$439,815———
Gross profit$-8,265$-21,888$-1M—$1M———
Operating income$-11M$-14M$-13M—$-16M$-12M$-22M—
Net income$-20M$-4M$-23M—$-20M$-46M$17M—
EPS (diluted)$-0.15$-0.05$-0.38—$-0.55$-1.50$0.72—

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$11M$8M$9M$8M$9M$8M$6M$15M
Inventory$5M$3M$3M$3M$4M$4M$3M—
Total current assets$23M$21M$17M$17M$21M$18M$16M$27M
Total assets$26M$22M$18M$19M$22M$19M$17M$29M
Long-term debt————————
Total liabilities$37M$51M$57M$51M$60M$52M$67M$102M
Total equity$-10M$-29M$-39M$-32M$-37M$-32M$-50M$-73M

Implied volatility — last 90 days

139%502%866%1229%1593% Jun 07 — IV 139% · EM ±19.3%Jun 08 — IV 570% · EM ±75.3%Jun 09 — IV 459% · EM ±57.5%Jun 10 — IV 339% · EM ±40.0%Jun 11 — IV 263% · EM ±29.0%Jun 12 — IV 285% · EM ±29.2%Jun 15 — IV 407% · EM ±29.4%Jun 16 — IV 249% · EM ±14.7%Jun 17 — IV 517% · EM ±21.6%Jun 19 — IV 186% · EM ±41.1%Jun 22 — IV 214% · EM ±44.7%Jun 23 — IV 184% · EM ±37.6%Jun 24 — IV 172% · EM ±34.4%Jun 25 — IV 189% · EM ±37.0%Jun 26 — IV 153% · EM ±29.2%Jun 29 — IV 216% · EM ±38.2%Jun 30 — IV 162% · EM ±27.9%Jul 01 — IV 193% · EM ±32.3%Jul 02 — IV 159% · EM ±25.7%Jul 03 — IV 166% · EM ±25.9%Jul 06 — IV 202% · EM ±28.0%Jul 07 — IV 194% · EM ±25.7%Jul 08 — IV 207% · EM ±25.9%Jul 09 — IV 202% · EM ±23.8%Jul 10 — IV 172% · EM ±19.0%Jul 13 — IV 172% · EM ±14.3%Jul 14 — IV 360% · EM ±26.0%Jul 15 — IV 266% · EM ±15.7%Jul 16 — IV 243% · EM ±10.1%Jul 20 — IV 295% · EM ±69.6%Jul 21 — IV 261% · EM ±60.8%Jul 22 — IV 316% · EM ±72.4%Jul 23 — IV 328% · EM ±73.9%Jul 24 — IV 220% · EM ±48.6%Jul 27 — IV 157% · EM ±32.7%Jul 28 — IV 206% · EM ±42.2%Jul 29 — IV 216% · EM ±43.4%Jul 30 — IV 173% · EM ±34.0%Jul 31 — IV 200% · EM ±38.3%Aug 03 — IV 215% · EM ±38.0%Aug 04 — IV 197% · EM ±33.9%Aug 05 — IV 190% · EM ±31.8%Aug 06 — IV 157% · EM ±25.4%Aug 07 — IV 171% · EM ±26.7%Aug 10 — IV 235% · EM ±32.6%Aug 11 — IV 235% · EM ±31.0%Aug 12 — IV 224% · EM ±28.1%Aug 13 — IV 243% · EM ±28.7%Aug 14 — IV 588% · EM ±64.9%Aug 17 — IV 531% · EM ±44.3%Aug 18 — IV 594% · EM ±43.0%Aug 19 — IV 851% · EM ±50.2%Aug 20 — IV 1593% · EM ±66.5%Aug 24 — IV 234% · EM ±48.9%Aug 25 — IV 267% · EM ±54.7%Aug 26 — IV 240% · EM ±48.1%Aug 27 — IV 232% · EM ±45.5%Aug 28 — IV 284% · EM ±54.3%Aug 31 — IV 311% · EM ±55.0%Sep 01 — IV 370% · EM ±63.7%Sep 02 — IV 286% · EM ±47.8%Sep 03 — IV 381% · EM ±61.6%Sep 04 — IV 387% · EM ±60.5%Sep 07 — IV 433% · EM ±60.0%Sep 08 — IV 470% · EM ±62.1%Sep 09 — IV 433% · EM ±54.2%Sep 10 — IV 390% · EM ±46.0%Sep 11 — IV 540% · EM ±59.7%Sep 14 — IV 565% · EM ±47.2%Sep 15 — IV 716% · EM ±51.8%Sep 16 — IV 996% · EM ±58.8%Sep 17 — IV 1055% · EM ±44.1%Sep 21 — IV 276% · EM ±57.6%Sep 22 — IV 246% · EM ±50.3%Sep 23 — IV 226% · EM ±45.3%Sep 24 — IV 272% · EM ±53.4%Sep 25 — IV 243% · EM ±46.6%Sep 28 — IV 269% · EM ±47.6%Oct 01 — IV 210% · EM ±34.0%Oct 02 — IV 322% · EM ±50.4%Oct 05 — IV 362% · EM ±50.2%

Sector peers

VYGR
Voyager Therapeutics, Inc.
$165M $1.75-13.1%
TARA
Protara Therapeutics, Inc.
$163M $2.35-5.8%
DTIL
Precision BioSciences, Inc.
$173M $6.63-1.2%
CHRS
Coherus Oncology, Inc.
$156M $1.01-1.0%
ABOS
Acumen Pharmaceuticals, Inc.
$150M $1.99-2.0%
CMPX
Compass Therapeutics, Inc.
$184M $0.76-7.1%

OTLK earnings FAQ

What is OTLK's expected move for earnings?

Options currently price a move of about ±50.2%, or $0.26 per share either way from $0.52.

How does OTLK stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.1%, up 0 times and down 2 times.

What is OTLK's implied volatility?

OTLK's at-the-money implied volatility is about 362% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in